Abionyx Pharma Partners With Axplora for CER-001 Manufacturing
Bitget2026/10/27 06:02- Abionyx Pharma entered a strategic manufacturing partnership with Axplora, completing the production network for its investigational biologic CER-001 alongside Texcell and Olon.
- Axplora will purify recombinant human apoA-I, CER-001's key biological component, at its Pompey site in France.
- The network supports preparations for potential initial marketing authorization in LCAT deficiency, subject to required validations.
- A Phase 2b sepsis trial, RACERS 2, is being prepared following €33 million in financing secured in June 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Positive outlook hinges on 1.1280 against US Dollar - UOB
USD/JPY Price Forecast: Remains close to 20-day EMA
OpenAI president confirms IPO in 2027: enterprise clients have become the main source of revenue, but funding target has shrunk from 30 billions to 20 billions
OpenAI President Brockman stated that enterprise sales have contributed the majority of the company's revenue, and the company will be ready for an IPO by 2027. OpenAI is accelerating fundraising and competing with Anthropic, which is aiming to go public by the end of the year.
Former Citi executive Klein establishes another SPAC; Churchill Capital XIV (CXIVU.US) plans to raise up to $300 million in US IPO
Churchill Capital XIV filed an application with the SEC on Wednesday, seeking to raise up to $300 million through an initial public offering (IPO).
Crypto prices
More
